Drug intelligence / Profile preview

RG023

Development stage: Preclinical
Lead developer: Rigerna Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RG023 is an investigational RNA-based therapeutic candidate being developed by Suzhou Xuanjing Biotechnology (also known as Rigerna Biotech). It is part of the company's kidney-targeted delivery platform, which is designed to deliver oligonucleotide therapeutics specifically to renal tissues. While the specific molecular target and mechanism of action are currently undisclosed, RG023 is being developed for the treatment of various kidney-related diseases. The program is currently in the early stages of development, leveraging Rigerna's proprietary RNA delivery technology.

Beyond the preview

Go deeper on RG023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG023.

Explore the full profile